# Microsoft Corp: financial statements, quarterly MSFT · Nasdaq · CIK 789019 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/msft.md) · [Financials](/companies/msft/financials.md) · [Filings](/companies/msft/filings.md) · [Insiders](/companies/msft/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/msft/financials.md?period=annual). ## Income statement | Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $bn | [62.0](/filings/0000950170-25-010491.md) | [61.9](/filings/0000950170-25-061046.md) | [64.7 d](/filings/0001193125-26-323660.md) | [65.6](/filings/0001193125-25-256321.md) | [69.6](/filings/0001193125-26-027207.md) | [70.1](/filings/0001193125-26-191507.md) | [76.4 d](/filings/0001193125-26-323660.md) | [77.7](/filings/0001193125-26-436133.md) | [81.3](/filings/0001193125-26-027207.md) | [82.9](/filings/0001193125-26-191507.md) | [90.0 d](/filings/0001193125-26-323660.md) | [92.3](/filings/0001193125-26-436133.md) | | Cost of revenue | $bn | [19.6](/filings/0000950170-25-010491.md) | [18.5](/filings/0000950170-25-061046.md) | [19.7 d](/filings/0001193125-26-323660.md) | [20.1](/filings/0001193125-25-256321.md) | [21.8](/filings/0001193125-26-027207.md) | [21.9](/filings/0001193125-26-191507.md) | [24.0 d](/filings/0001193125-26-323660.md) | [24.0](/filings/0001193125-26-436133.md) | [26.0](/filings/0001193125-26-027207.md) | [26.8](/filings/0001193125-26-191507.md) | [29.5 d](/filings/0001193125-26-323660.md) | [29.7](/filings/0001193125-26-436133.md) | | Gross profit | $bn | [42.4](/filings/0000950170-25-010491.md) | [43.4](/filings/0000950170-25-061046.md) | [45.0 d](/filings/0001193125-26-323660.md) | [45.5](/filings/0001193125-25-256321.md) | [47.8](/filings/0001193125-26-027207.md) | [48.1](/filings/0001193125-26-191507.md) | [52.4 d](/filings/0001193125-26-323660.md) | [53.6](/filings/0001193125-26-436133.md) | [55.3](/filings/0001193125-26-027207.md) | [56.1](/filings/0001193125-26-191507.md) | [60.5 d](/filings/0001193125-26-323660.md) | [62.6](/filings/0001193125-26-436133.md) | | Research and development | $bn | [7.1](/filings/0000950170-25-010491.md) | [7.7](/filings/0000950170-25-061046.md) | [8.1 d](/filings/0001193125-26-323660.md) | [7.5](/filings/0001193125-25-256321.md) | [7.9](/filings/0001193125-26-027207.md) | [8.2](/filings/0001193125-26-191507.md) | [8.8 d](/filings/0001193125-26-323660.md) | [8.1](/filings/0001193125-26-436133.md) | [8.5](/filings/0001193125-26-027207.md) | [8.9](/filings/0001193125-26-191507.md) | [10.0 d](/filings/0001193125-26-323660.md) | [9.0](/filings/0001193125-26-436133.md) | | Operating income | $bn | [27.0](/filings/0000950170-25-010491.md) | [27.6](/filings/0000950170-25-061046.md) | [27.9 d](/filings/0001193125-26-323660.md) | [30.6](/filings/0001193125-25-256321.md) | [31.7](/filings/0001193125-26-027207.md) | [32.0](/filings/0001193125-26-191507.md) | [34.3 d](/filings/0001193125-26-323660.md) | [38.0](/filings/0001193125-26-436133.md) | [38.3](/filings/0001193125-26-027207.md) | [38.4](/filings/0001193125-26-191507.md) | [40.6 d](/filings/0001193125-26-323660.md) | [45.9](/filings/0001193125-26-436133.md) | | Interest expense | $bn | [0.9](/filings/0000950170-24-008814.md) | [0.8](/filings/0000950170-24-048288.md) | [0.7 d](/filings/0000950170-24-087843.md) | [0.6](/filings/0001193125-25-256321.md) | [0.6](/filings/0001193125-26-027207.md) | [0.6](/filings/0001193125-26-191507.md) | [0.6 d](/filings/0001193125-26-323660.md) | [0.7](/filings/0001193125-26-436133.md) | [0.7](/filings/0001193125-26-027207.md) | [0.8](/filings/0001193125-26-191507.md) | [0.8 d](/filings/0001193125-26-323660.md) | [0.9](/filings/0001193125-26-436133.md) | | Income tax | $bn | [4.7](/filings/0000950170-25-010491.md) | [4.8](/filings/0000950170-25-061046.md) | [5.2 d](/filings/0001193125-26-323660.md) | [5.6](/filings/0001193125-25-256321.md) | [5.3](/filings/0001193125-26-027207.md) | [5.6](/filings/0001193125-26-191507.md) | [5.4 d](/filings/0001193125-26-323660.md) | [6.6](/filings/0001193125-26-436133.md) | [9.8](/filings/0001193125-26-027207.md) | [7.6](/filings/0001193125-26-191507.md) | [8.3 d](/filings/0001193125-26-323660.md) | [9.3](/filings/0001193125-26-436133.md) | | Net income | $bn | [21.9](/filings/0000950170-25-010491.md) | [21.9](/filings/0000950170-25-061046.md) | [22.0 d](/filings/0001193125-26-323660.md) | [24.7](/filings/0001193125-25-256321.md) | [24.1](/filings/0001193125-26-027207.md) | [25.8](/filings/0001193125-26-191507.md) | [27.2 d](/filings/0001193125-26-323660.md) | [27.7](/filings/0001193125-26-436133.md) | [38.5](/filings/0001193125-26-027207.md) | [31.8](/filings/0001193125-26-191507.md) | [35.8 d](/filings/0001193125-26-323660.md) | [36.6](/filings/0001193125-26-436133.md) | | Diluted EPS | $ per share | [2.93](/filings/0000950170-25-010491.md) | [2.94](/filings/0000950170-25-061046.md) | not reported | [3.30](/filings/0001193125-25-256321.md) | [3.23](/filings/0001193125-26-027207.md) | [3.46](/filings/0001193125-26-191507.md) | not reported | [3.72](/filings/0001193125-26-436133.md) | [5.16](/filings/0001193125-26-027207.md) | [4.27](/filings/0001193125-26-191507.md) | not reported | [4.92](/filings/0001193125-26-436133.md) | | Basic EPS | $ per share | [2.94](/filings/0000950170-25-010491.md) | [2.95](/filings/0000950170-25-061046.md) | not reported | [3.32](/filings/0001193125-25-256321.md) | [3.24](/filings/0001193125-26-027207.md) | [3.47](/filings/0001193125-26-191507.md) | not reported | [3.73](/filings/0001193125-26-436133.md) | [5.18](/filings/0001193125-26-027207.md) | [4.28](/filings/0001193125-26-191507.md) | not reported | [4.93](/filings/0001193125-26-436133.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [17.3](/filings/0000950170-24-008814.md) | [19.6](/filings/0000950170-24-048288.md) | [18.3](/filings/0000950170-25-100235.md) | [20.8](/filings/0000950170-24-118967.md) | [17.5](/filings/0000950170-25-010491.md) | [28.8](/filings/0000950170-25-061046.md) | [30.2](/filings/0001193125-26-323660.md) | [28.8](/filings/0001193125-25-256321.md) | [24.3](/filings/0001193125-26-027207.md) | [32.1](/filings/0001193125-26-191507.md) | [20.9](/filings/0001193125-26-436133.md) | [20.3](/filings/0001193125-26-436133.md) | | Current assets | $bn | [147](/filings/0000950170-24-008814.md) | [147](/filings/0000950170-24-048288.md) | [160](/filings/0000950170-25-100235.md) | [150](/filings/0000950170-24-118967.md) | [147](/filings/0000950170-25-010491.md) | [157](/filings/0000950170-25-061046.md) | [191](/filings/0001193125-26-323660.md) | [189](/filings/0001193125-25-256321.md) | [180](/filings/0001193125-26-027207.md) | [175](/filings/0001193125-26-191507.md) | [208](/filings/0001193125-26-436133.md) | [186](/filings/0001193125-26-436133.md) | | Total assets | $bn | [471](/filings/0000950170-24-008814.md) | [484](/filings/0000950170-24-048288.md) | [512](/filings/0000950170-25-100235.md) | [523](/filings/0000950170-24-118967.md) | [534](/filings/0000950170-25-010491.md) | [563](/filings/0000950170-25-061046.md) | [619](/filings/0001193125-26-323660.md) | [636](/filings/0001193125-25-256321.md) | [665](/filings/0001193125-26-027207.md) | [694](/filings/0001193125-26-191507.md) | [758](/filings/0001193125-26-436133.md) | [779](/filings/0001193125-26-436133.md) | | Current liabilities | $bn | [121](/filings/0000950170-24-008814.md) | [119](/filings/0000950170-24-048288.md) | [125](/filings/0000950170-25-100235.md) | [115](/filings/0000950170-24-118967.md) | [109](/filings/0000950170-25-010491.md) | [114](/filings/0000950170-25-061046.md) | [141](/filings/0001193125-26-323660.md) | [135](/filings/0001193125-25-256321.md) | [130](/filings/0001193125-26-027207.md) | [137](/filings/0001193125-26-191507.md) | [169](/filings/0001193125-26-436133.md) | [152](/filings/0001193125-26-436133.md) | | Total liabilities | $bn | [232](/filings/0000950170-24-008814.md) | [231](/filings/0000950170-24-048288.md) | [244](/filings/0000950170-25-100235.md) | [235](/filings/0000950170-24-118967.md) | [231](/filings/0000950170-25-010491.md) | [241](/filings/0000950170-25-061046.md) | [276](/filings/0001193125-26-323660.md) | [273](/filings/0001193125-25-256321.md) | [274](/filings/0001193125-26-027207.md) | [280](/filings/0001193125-26-191507.md) | [316](/filings/0001193125-26-436133.md) | [309](/filings/0001193125-26-436133.md) | | Long-term debt | $bn | [44.9](/filings/0000950170-24-008814.md) | [42.7](/filings/0000950170-24-048288.md) | [42.7](/filings/0000950170-25-100235.md) | [42.9](/filings/0000950170-24-118967.md) | [39.7](/filings/0000950170-25-010491.md) | [39.9](/filings/0000950170-25-061046.md) | [40.2](/filings/0001193125-26-323660.md) | [35.4](/filings/0001193125-25-256321.md) | [35.4](/filings/0001193125-26-027207.md) | [31.4](/filings/0001193125-26-191507.md) | [31.1](/filings/0001193125-26-436133.md) | [31.1](/filings/0001193125-26-436133.md) | | Current portion of debt | $bn | [2.3](/filings/0000950170-24-008814.md) | [2.2](/filings/0000950170-24-048288.md) | [2.2](/filings/0000950170-25-100235.md) | [2.2](/filings/0000950170-24-118967.md) | [5.2](/filings/0000950170-25-010491.md) | [3.0](/filings/0000950170-25-061046.md) | [3.0](/filings/0001193125-26-323660.md) | [7.8](/filings/0001193125-25-256321.md) | [4.8](/filings/0001193125-26-027207.md) | [8.8](/filings/0001193125-26-191507.md) | [9.2](/filings/0001193125-26-436133.md) | [4.4](/filings/0001193125-26-436133.md) | | Short-term borrowings | $bn | [27.0](/filings/0000950170-24-008814.md) | [20.5](/filings/0000950170-24-048288.md) | [6.7](/filings/0000950170-25-100235.md) | [0.0](/filings/0000950170-24-118967.md) | [0.0](/filings/0000950170-25-010491.md) | [0.0](/filings/0000950170-25-061046.md) | [0.0](/filings/0000950170-25-100235.md) | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $bn | [238](/filings/0000950170-25-010491.md) | [253](/filings/0000950170-25-061046.md) | [268](/filings/0001193125-26-323660.md) | [288](/filings/0001193125-25-256321.md) | [303](/filings/0001193125-26-027207.md) | [322](/filings/0001193125-26-191507.md) | [343](/filings/0001193125-26-323660.md) | [363](/filings/0001193125-26-436133.md) | [391](/filings/0001193125-26-027207.md) | [414](/filings/0001193125-26-191507.md) | [442](/filings/0001193125-26-436133.md) | [471](/filings/0001193125-26-436133.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: us-gaap:CommercialPaper - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $bn | [18.9](/filings/0000950170-25-010491.md) | [31.9](/filings/0000950170-25-061046.md) | [37.2 d](/filings/0001193125-26-323660.md) | [34.2](/filings/0001193125-25-256321.md) | [22.3](/filings/0001193125-26-027207.md) | [37.0](/filings/0001193125-26-191507.md) | [42.6 d](/filings/0001193125-26-323660.md) | [45.1](/filings/0001193125-26-436133.md) | [35.8](/filings/0001193125-26-027207.md) | [46.7](/filings/0001193125-26-191507.md) | [55.4 d](/filings/0001193125-26-323660.md) | [58.0](/filings/0001193125-26-436133.md) | | Capital expenditure | $bn | [9.7](/filings/0000950170-25-010491.md) | [11.0](/filings/0000950170-25-061046.md) | [13.9 d](/filings/0001193125-26-323660.md) | [14.9](/filings/0001193125-25-256321.md) | [15.8](/filings/0001193125-26-027207.md) | [16.7](/filings/0001193125-26-191507.md) | [17.1 d](/filings/0001193125-26-323660.md) | [19.4](/filings/0001193125-26-436133.md) | [29.9](/filings/0001193125-26-027207.md) | [30.9](/filings/0001193125-26-191507.md) | [35.8 d](/filings/0001193125-26-323660.md) | [39.4](/filings/0001193125-26-436133.md) | | Dividends paid | $bn | [5.6](/filings/0000950170-25-010491.md) | [5.6](/filings/0000950170-25-061046.md) | [5.6 d](/filings/0001193125-26-323660.md) | [5.6](/filings/0001193125-25-256321.md) | [6.2](/filings/0001193125-26-027207.md) | [6.2](/filings/0001193125-26-191507.md) | [6.2 d](/filings/0001193125-26-323660.md) | [6.2](/filings/0001193125-26-436133.md) | [6.8](/filings/0001193125-26-027207.md) | [6.8](/filings/0001193125-26-191507.md) | [6.8 d](/filings/0001193125-26-323660.md) | [6.8](/filings/0001193125-26-436133.md) | | Share repurchases | $bn | [4.0](/filings/0000950170-25-010491.md) | [4.2](/filings/0000950170-25-061046.md) | [4.2 d](/filings/0001193125-26-323660.md) | [4.1](/filings/0001193125-25-256321.md) | [5.0](/filings/0001193125-26-027207.md) | [4.8](/filings/0001193125-26-191507.md) | [4.5 d](/filings/0001193125-26-323660.md) | [5.7](/filings/0001193125-26-436133.md) | [7.4](/filings/0001193125-26-027207.md) | [4.6](/filings/0001193125-26-191507.md) | [4.6 d](/filings/0001193125-26-323660.md) | [4.4](/filings/0001193125-26-436133.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q1 FY2027 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [7,473](/filings/0000950170-24-008814.md) | [7,464](/filings/0000950170-24-048288.md) | [7,462](/filings/0000950170-24-118967.md) | [7,468](/filings/0000950170-25-010491.md) | [7,472](/filings/0000950170-25-061046.md) | [7,470](/filings/0001193125-25-256321.md) | [7,468](/filings/0001193125-26-027207.md) | [7,461](/filings/0001193125-26-191507.md) | [7,466](/filings/0001193125-26-436133.md) | [7,460](/filings/0001193125-26-027207.md) | [7,445](/filings/0001193125-26-191507.md) | [7,446](/filings/0001193125-26-436133.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 7,426,194,552 at 2026-10-22, from the cover of the [10-Q filed 2026-10-28](/filings/0001193125-26-436133.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 05:26 ET. No prices; not investment advice.